[go: up one dir, main page]

ECSP13012384A - Composición acuosa que contiene bromhexina - Google Patents

Composición acuosa que contiene bromhexina

Info

Publication number
ECSP13012384A
ECSP13012384A ECSP13012384A ECSP13012384A EC SP13012384 A ECSP13012384 A EC SP13012384A EC SP13012384 A ECSP13012384 A EC SP13012384A EC SP13012384 A ECSP13012384 A EC SP13012384A
Authority
EC
Ecuador
Prior art keywords
composition containing
containing bromhexine
bromhexine
aquous
aquous composition
Prior art date
Application number
Other languages
English (en)
Inventor
Uwe Scheuring
Bernd Plohmann
Annette Zamponi
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43063562&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012384(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ECSP13012384A publication Critical patent/ECSP13012384A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

La presente invención se refiere a una composición acuosa que contiene bromhexina, en donde la composición tiene una cantidad de azúcar-alcoholes inferior a 10 g referida a 100 ml de la composición, y a su empleo para la terapia secretórica en enfermedades broncopulmonares agudas y crónicas.
ECSP13012384 2010-07-12 2013-01-12 Composición acuosa que contiene bromhexina ECSP13012384A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10169236 2010-07-12

Publications (1)

Publication Number Publication Date
ECSP13012384A true ECSP13012384A (es) 2013-03-28

Family

ID=43063562

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012384 ECSP13012384A (es) 2010-07-12 2013-01-12 Composición acuosa que contiene bromhexina

Country Status (27)

Country Link
US (1) US9220693B2 (es)
EP (1) EP2593094B1 (es)
JP (1) JP5979763B2 (es)
KR (1) KR101943812B1 (es)
CN (1) CN103052384B (es)
AR (1) AR082381A1 (es)
AU (1) AU2011278451B2 (es)
BR (1) BR112013000537B1 (es)
CA (1) CA2803471C (es)
CL (1) CL2012003625A1 (es)
CO (1) CO6680609A2 (es)
CY (1) CY1120079T1 (es)
DK (1) DK2593094T3 (es)
EA (1) EA025640B1 (es)
EC (1) ECSP13012384A (es)
ES (1) ES2661973T3 (es)
HR (1) HRP20180396T1 (es)
HU (1) HUE038399T2 (es)
LT (1) LT2593094T (es)
MX (1) MX337454B (es)
PE (1) PE20131063A1 (es)
PH (1) PH12013500081B1 (es)
PL (1) PL2593094T3 (es)
PT (1) PT2593094T (es)
SG (1) SG187016A1 (es)
SI (1) SI2593094T1 (es)
WO (1) WO2012007352A1 (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20180396T1 (hr) 2010-07-12 2018-04-20 Sanofi-Aventis Deutschland Gmbh Vodeni pripravak koji sadrži bromheksin
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
US9642915B2 (en) 2012-05-07 2017-05-09 Cellix Bio Private Limited Compositions and methods for the treatment of neuromuscular disorders and neurodegenerative diseases
CA2872975A1 (en) 2012-05-07 2013-11-14 Cellixbio Private Limited Compositions and methods for the treatment of neurological disorders
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
US9309233B2 (en) 2012-05-08 2016-04-12 Cellix Bio Private Limited Compositions and methods for the treatment of blood clotting disorders
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
US9403857B2 (en) 2012-05-10 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
CA2873104A1 (en) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions and methods for the treatment of mucositis
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
CN104603097A (zh) 2012-05-23 2015-05-06 塞利克斯比奥私人有限公司 用于治疗多发性硬化症的组合物和方法
EP2852570B1 (en) 2012-05-23 2020-04-22 Cellixbio Private Limited Composition for the treatment of inflammatory bowel disease
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
CN104364231A (zh) 2012-09-08 2015-02-18 塞利克斯比奥私人有限公司 用于治疗炎症和脂质异常的组合物和方法
JP6017249B2 (ja) * 2012-09-28 2016-10-26 小林製薬株式会社 経口投与用液体医薬組成物
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
EP3004049B1 (en) 2013-06-04 2018-09-05 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
CN103893116B (zh) * 2014-04-17 2015-12-09 河北仁合益康药业有限公司 一种盐酸溴己新口服液组合物
MX2016015303A (es) * 2014-05-23 2017-03-06 Boehringer Ingelheim Int Jarabe para la tos que contiene clorhidrato de ambroxol.
EP3240779B1 (en) 2014-09-26 2020-10-28 Cellixbio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
WO2016051420A1 (en) 2014-09-29 2016-04-07 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
EP3212626B1 (en) 2014-10-27 2018-11-07 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
SG11201705524SA (en) 2015-01-06 2017-08-30 Cellix Bio Private Ltd Compositions and methods for the treatment of inflammation and pain
CN111568861A (zh) * 2020-05-25 2020-08-25 河北科星药业有限公司 畜禽用盐酸溴己新口服液及其制备方法和应用
CN111714477B (zh) * 2020-07-23 2021-06-15 山东迅达康兽药有限公司 祛痰组合物及其口服液制备方法
CN113109463B (zh) * 2021-03-16 2022-11-25 浙江工业大学 一种复方氯丙那林溴己新胶囊中有关物质的检测方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH085784B2 (ja) 1987-06-17 1996-01-24 興和株式会社 シロツプ剤
US5624906A (en) * 1994-12-08 1997-04-29 Lever Brothers Company, Division Of Conopco, Inc. Oral hygiene compositions comprising heteroatom containing alkyl aldonamide compounds
CN1220598A (zh) * 1996-05-02 1999-06-23 大正制药株式会社 水难溶性酸性药物的悬浮液
JP3800437B2 (ja) 1996-07-24 2006-07-26 大正製薬株式会社 苦味が軽減された液剤
JPH10101581A (ja) 1996-09-26 1998-04-21 Taisho Pharmaceut Co Ltd 塩酸ブロムヘキシンの安定化製剤及び安定化方法
JPH10306038A (ja) 1997-05-07 1998-11-17 Taisho Pharmaceut Co Ltd ブロムヘキシン含有液剤
JP2000281562A (ja) * 1999-03-30 2000-10-10 Taisho Pharmaceut Co Ltd ゲル状組成物
JP2001106639A (ja) * 1999-10-04 2001-04-17 Taisho Pharmaceut Co Ltd 経口用組成物
EP1121940A1 (en) * 2000-01-31 2001-08-08 New Pharma Research Sweden AB Pharmaceutical compositions comprising an antibiotic and bromhexine, and process for their preparation
JP2002081562A (ja) 2000-09-05 2002-03-22 Kayaba Ind Co Ltd リリーフ弁
US6692725B2 (en) * 2001-02-19 2004-02-17 Daicel Chemical Industries, Ltd. Composition for oral care
US7138133B2 (en) * 2001-10-10 2006-11-21 The Procter & Gamble Company Orally administered liquid compositions
JP5134802B2 (ja) * 2005-09-29 2013-01-30 第一三共ヘルスケア株式会社 塩酸ブロムヘキシン含有量低下の防止方法
US10022339B2 (en) * 2006-04-21 2018-07-17 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
JP2008013542A (ja) * 2006-06-07 2008-01-24 Daiichi Sankyo Healthcare Co Ltd 去痰又は気道杯細胞過形成抑制のための医薬組成物
CN100409835C (zh) * 2007-04-06 2008-08-13 张嵩 含有溴己新盐的组合物及大容量注射剂和注射剂制备方法
KR101025498B1 (ko) * 2008-05-02 2011-03-31 (주)이엘티사이언스 염산브롬헥신 경구용 액제 복합조성물 및 그 제조방법
HRP20180396T1 (hr) 2010-07-12 2018-04-20 Sanofi-Aventis Deutschland Gmbh Vodeni pripravak koji sadrži bromheksin

Also Published As

Publication number Publication date
PT2593094T (pt) 2018-03-12
LT2593094T (lt) 2018-03-26
CO6680609A2 (es) 2013-05-31
AU2011278451B2 (en) 2014-11-27
AU2011278451A1 (en) 2013-01-24
EP2593094B1 (de) 2017-12-06
BR112013000537A2 (pt) 2016-05-24
PL2593094T3 (pl) 2018-05-30
WO2012007352A1 (de) 2012-01-19
BR112013000537B1 (pt) 2021-07-27
EA201201659A1 (ru) 2013-06-28
MX337454B (es) 2016-03-07
SI2593094T1 (en) 2018-04-30
US20130267605A1 (en) 2013-10-10
DK2593094T3 (en) 2018-03-12
HRP20180396T1 (hr) 2018-04-20
CY1120079T1 (el) 2018-12-12
EP2593094A1 (de) 2013-05-22
KR20130100091A (ko) 2013-09-09
ES2661973T3 (es) 2018-04-04
AR082381A1 (es) 2012-12-05
PE20131063A1 (es) 2013-10-12
PH12013500081B1 (en) 2017-09-27
MX2013000417A (es) 2013-02-07
SG187016A1 (en) 2013-02-28
HUE038399T2 (hu) 2018-10-29
CL2012003625A1 (es) 2013-05-31
KR101943812B1 (ko) 2019-01-31
CA2803471C (en) 2019-01-15
CN103052384A (zh) 2013-04-17
CA2803471A1 (en) 2012-01-19
CN103052384B (zh) 2017-04-05
PH12013500081A1 (en) 2013-03-18
US9220693B2 (en) 2015-12-29
JP5979763B2 (ja) 2016-08-31
JP2013531017A (ja) 2013-08-01
EA025640B1 (ru) 2017-01-30

Similar Documents

Publication Publication Date Title
ECSP13012384A (es) Composición acuosa que contiene bromhexina
CY1121203T1 (el) Θεραπευτικες χρησεις της εμπαγλιφλοζινης
CL2012000620A1 (es) Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20.
CL2015003731A1 (es) Inhibidores de bromodominios
PE20191796A1 (es) Composicion farmaceutica de clorhidrato de s-ketamina
AR098168A1 (es) Formulación estable de insulina glulisina
MX367241B (es) Uso de anticuerpos contra claudina 18.2 en una terapia de combinación para el tratamiento de cáncer.
CO6280490A2 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
BR112015005369A2 (pt) inibidores de usp30 e métodos para sua utilização
BR112012026707A2 (pt) uso de um anticorpo anti-cd20 afucosilado, composição que compreende um anticorpo anti-cd20 afucosilado e método de tratamento de pacientes que sofrem de câncer por meio da administração de um anticorpo anti-cd20 afucosilado
UA115811C2 (uk) Стабільний розчин об'єднаних баклофену, сорбіту і налтрексону для перорального застосування
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112015029462A8 (pt) Inibidores de quinase
AR092151A1 (es) Preparacion farmaceutica solida que contiene levotiroxina
MX2011006725A (es) Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20.
EA201491300A1 (ru) Композиция для назального применения с улучшенной стабильностью
AR082215A1 (es) Composicion farmaceutica agradable al paladar
PL405125A1 (pl) Cząsteczka miR172 pochodzenia roślinnego lub jej syntetyczny ekwiwalent, sposób zmniejszania proliferacji limfocytów B oraz zastosowanie cząsteczki miR172
BR112013000840A2 (pt) método para aumentar o efeito de forma ativada potencializada de anticorpo para molécula endógena biológica, composição farmacêutica e uso de combinação de molécula biológica endógena com forma ativada potencializada de anticorpo para a sintase no endotelial.
EA201101126A1 (ru) Фармацевтическая композиция и способ увеличения роста волос
BR112015017432A2 (pt) métodos para o tratamento de indicações cardiovasculares
UY34267A (es) Métodos para aumentar el contenido de proteínas,aceites y/o aminoácidos en una planta
BR112015031585A2 (pt) composição farmacêutica
MX362686B (es) Inmunógenos fúngicos y materiales y métodos relacionados.
BR112015004494A2 (pt) célula de fluxo de permeabilidade e sistema de condutância hidráulica